Sartorius (SRT) Q4 2024 earnings summary

Executive summary

• Achieved 2024 guidance with sales revenue of €3,381 million, flat year-over-year in constant currencies, and strong Q4 performance as market recovery gained momentum.

• Underlying growth drivers, especially in consumables and advanced therapies, returned as temporary market volatilities subsided.

• Profitability remained robust, supported by efficiency programs that offset lower capacity utilization and inventory reduction.

• Lab Products & Services sales were slightly below prior year due to soft end markets, especially in China, but profitability was maintained.

• Outlook for 2025 is cautious, expecting moderate, profitable growth above market rates, led by Bioprocess Solutions.

Financial highlights

• 2024 sales reached €3.4 billion, flat year-over-year (+0.1% in constant currencies); order intake rose 10.8%.

• Recurring business (consumables) grew mid-single digits, while equipment sales declined double digits.

• Underlying EBITDA margin was 28.0% (€945 million), matching guidance midpoint; underlying EPS (ord.) was €4.05.

• Free cash flow doubled to €550 million, driven by working capital and CapEx management; operating cash flow increased 14.4% to €976 million.

• CapEx as a percentage of sales reduced from 16.5% to 12.1%.

Outlook and guidance

• 2025 expected to see profitable, moderate revenue growth above market, with slight EBITDA margin expansion; Bioprocess Solutions to drive growth.

• Quantitative guidance to be provided with Q1 results in April; midterm targets remain unchanged.

• Focus remains on organic debt reduction, working capital, and investment management.